<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective is to report a patient with concomitant <z:e sem="disease" ids="C0038013" disease_type="Disease or Syndrome" abbrv="">ankylosing spondylitis</z:e> (AS) and <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) successfully treated with adalimumab </plain></SENT>
<SENT sid="1" pm="."><plain>A 44-year-old male diagnosed as AS applied to our outpatient clinic with complaints of morning stiffness, pain and limitation of motion at spine, concurrence of oral and genital ulcerated lesions </plain></SENT>
<SENT sid="2" pm="."><plain>He was on <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> together with different <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> for the past 1 year </plain></SENT>
<SENT sid="3" pm="."><plain>According to the criteria of International Study Group, he was diagnosed as BD </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was considered as refractory to current treatment and adalimumab treatment was started </plain></SENT>
<SENT sid="5" pm="."><plain>During follow-up, not only AS was in remission, but also no new oral and <z:e sem="disease" ids="C0151281" disease_type="Disease or Syndrome" abbrv="">genital ulcerations</z:e> appeared </plain></SENT>
<SENT sid="6" pm="."><plain>There were no complications related to the use of anti-TNFalpha therapy </plain></SENT>
<SENT sid="7" pm="."><plain>In our case it was observed that anti-TNFalpha therapy, specifically adalimumab, was effective for symptoms of both AS and BD </plain></SENT>
</text></document>